Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats - Wikidata - awgldk - TriplyDB

Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats

Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats

http://www.wikidata.org/entity/Q33902393

about

Type IV collagen is transcriptionally regulated by Smad1 under advanced glycation end product (AGE) stimulation.Blockade of advanced glycation end-product formation restores ischemia-induced angiogenesis in diabetic mice Endothelial dysfunction in diabetes.Role of vascular risk factors and vascular dysfunction in Alzheimer's disease.Therapeutic relevance of ozone therapy in degenerative diseases: Focus on diabetes and spinal pain.Clinical applications of arterial stiffness: therapeutics and pharmacology.Aminoguanidine prevents age-related aortic stiffening in Fisher 344 rats: aortic impedance analysis.An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness.Medical treatment of diabetic retinopathy.Aminoguanidine prevents arterial stiffening and cardiac hypertrophy in streptozotocin-induced diabetes in rats.Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy Aminoguanidine prevents fructose-induced deterioration in left ventricular-arterial coupling in Wistar rats.Effects of olmesartan on arterial stiffness in rats with chronic renal failure.Breakers of advanced glycation end products restore large artery properties in experimental diabetes.Inhibition of advanced glycation endproduct formation by acetaldehyde: role in the cardioprotective effect of ethanol.Vascular hypertrophy in experimental diabetes. Role of advanced glycation end products.Prevention of arterial stiffening by pyridoxamine in diabetes is associated with inhibition of the pathogenic glycation on aortic collagen Current therapeutic interventions in the glycation pathway: evidence from clinical studies.Advanced glycation end products: role in pathology of diabetic cardiomyopathy.Molecular strategies to prevent, inhibit, and degrade advanced glycoxidation and advanced lipoxidation end products.Novel therapeutic targets in the management of atrial fibrillation.Advanced glycation end-products and atherosclerosis.Oxidative stress and lipids in diabetes: a role in endothelium vasodilator dysfunction?Mechanical properties of the common carotid artery in Williams syndrome.Pharmacological prevention of cardiovascular aging--targeting the Maillard reaction Aldosterone receptor inhibition alters the viscoelastic biomechanical behavior of the aortic wall.Nitric oxide-mediated corpus cavernosal smooth muscle relaxation is impaired in ageing and diabetes.Role of advanced glycation end products in mobility and considerations in possible dietary and nutritional intervention strategies

P2860

Q31036740-6D5FDBC9-E6A5-4B7E-83D7-677F5A58CF86 Q31146191-0B463C22-C8F9-46A2-8D62-9DFE00522479 Q33959485-080FB2A3-CB9A-4BE6-A8E5-77345379ED27 Q34055011-B17E1EFF-48FA-42C4-B183-38BD8C9E64C9 Q34557662-848D7C9A-BFF4-458C-A831-FF17EDF3548F Q34647819-29EAC6E2-DEA6-421C-B895-8B5C2A4647F1 Q35045662-7C670342-6491-48C0-84E6-7114849D373C Q35081898-DAD56D96-EB6B-43BD-B1E6-2B453B0E997D Q35175679-DF83F0CF-BFA2-4A56-B4C3-309F0F586479 Q35566544-6420634A-7661-48EF-AD65-5AC280A7AF5C Q35805813-7AAC7C5D-FC92-4B37-9DE7-9705F4481953 Q36052796-173E1F7E-3F86-4DB7-B369-66DF294757A1 Q36320297-1B0081FB-7EC0-4A17-9F95-86F48E251A19 Q36477705-D33BFF39-813E-4130-A7C3-81F44501E85E Q37184929-994F8192-2DFC-49B2-89C2-51FB194E0FFB Q37364608-E4DC1947-1953-4AAE-A0BD-2E69FD287108 Q37395276-288B18EE-531F-40FF-A90F-72376679CA73 Q38070906-1CA4E9FE-4AC2-499D-807E-152D051BDC7D Q38081119-41DED6A6-BFB8-4452-8284-CC25D6D0321B Q38096444-8BC7EF2B-70C7-4B7C-A367-0953FFB690E9 Q38236746-5B7CE081-8233-4341-9D77-7D76031B3853 Q41250355-2263C975-9C4F-4052-B975-6A90A5A52617 Q41740391-75C9264E-BFA7-43EA-9A90-2CBE430A9700 Q41869648-80EBE2DC-5FAD-4CF1-AF1D-93E4DD4E496E Q42126940-9BFD1E78-0E4E-4465-A159-18D754430B75 Q43093139-A88F94AA-200B-4DEC-9EB8-29EA1E25515C Q43543926-2E805456-7499-488E-8348-12F05C74334F Q58577346-44AF86B8-5CD1-4A94-AFA2-726DDDFC8B7A

P2860

Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats

http://www.wikidata.org/entity/Q33902393

description

1993 nî lūn-bûn

@nan

1993 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

1993 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

1993年の論文

@ja

1993年論文

@yue

1993年論文

@zh-hant

1993年論文

@zh-hk

1993年論文

@zh-mo

1993年論文

@zh-tw

1993年论文

@wuu

name

Aminoguanidine treatment incre ...... ge arteries from diabetic rats

@ast

Aminoguanidine treatment incre ...... ge arteries from diabetic rats

@en

type

label

Aminoguanidine treatment incre ...... ge arteries from diabetic rats

@ast

Aminoguanidine treatment incre ...... ge arteries from diabetic rats

@en

prefLabel

Aminoguanidine treatment incre ...... ge arteries from diabetic rats

@ast

Aminoguanidine treatment incre ...... ge arteries from diabetic rats

@en

P1433

Q33902393-D4237C62-1224-4D64-A1CA-0C696D8F95FD

P1476

Q33902393-E4B97C31-CBFF-46FF-92DD-14A4EF6702C9

P2093

Q33902393-117EE31A-5721-4DB3-9523-9DD7EA295146

Q33902393-2B21DC4C-B5AD-4F06-8F7B-56CBCF464764

Q33902393-333E3936-1222-44A4-AE85-CC01DCDB275A

Q33902393-4C0BD480-F8E3-4AD5-91FE-1A8D085CDDEB

Q33902393-6E2843DE-1A4D-4F9B-9C47-4D8A065D9F4C

Q33902393-A969D424-BC60-4797-A47E-B9C5F557E4B5

Q33902393-F7D0A6EA-A8C0-4A73-8905-0AD14A54B02E

P2860

Q33902393-033AAF61-88FF-4EEE-8644-C8704CF5E4E4

Q33902393-03675A4D-F43C-4C55-866E-A3F4E3EF8EAA

Q33902393-2B84677C-D9F3-4139-ABB5-70E0F25297D9

Q33902393-4AB96652-4C50-4A5B-8007-621A83926F17

Q33902393-645969ED-7618-4EB3-B6BF-C6045E25CC7C

Q33902393-6CDD8998-0C2A-45B7-BB10-1151B5D76241

Q33902393-76879861-8C3E-4B8B-A319-285487874516

Q33902393-7FA6E778-FB09-4F76-B948-F6536292DFC7

Q33902393-83FB7B56-BD3C-4342-906C-25E54B21E5D4

Q33902393-A0A873FD-CF26-4632-8174-2523F0EB29FF

P304

Q33902393-E5E3EF38-F14F-4816-860A-FEAF1F939F6C

P31

Q33902393-585F1D63-79B5-4DE8-A102-CD9D3C33DC30

P356

Q33902393-F2FB858E-A1CE-4BFE-81D6-52162142C109

P407

Q33902393-0156BEBB-3AEE-4D66-B4AD-059F74B2E102

P433

Q33902393-13C9D9D5-50D0-4F51-98F7-99306E1248C2

P478

Q33902393-20CA4937-93B4-484C-87B4-E9A6FDF85DF1

P577

Q33902393-6525B7C6-2A29-4B7D-BD9E-0FF4CB22EEB9

P698

Q33902393-BDA2ABF0-6AF3-45BD-A39B-D9D598B2AA26

P932

Q33902393-EE21CFF3-858A-4319-98EC-5F3C6B11EC09

P356

P1433

Journal of Clinical Investigation

P1476

Aminoguanidine treatment incre ...... ge arteries from diabetic rats

@en

P2093

Boudier HA

http://www.w3.org/2001/XMLSchema#string

Crijns FR

http://www.w3.org/2001/XMLSchema#string

Huijberts MS

http://www.w3.org/2001/XMLSchema#string

Kruseman AC

http://www.w3.org/2001/XMLSchema#string

Lévy BI

http://www.w3.org/2001/XMLSchema#string

Poitevin P

http://www.w3.org/2001/XMLSchema#string

Wolffenbuttel BH

http://www.w3.org/2001/XMLSchema#string

P2860

Arterial and venous compliance in sustained essential hypertension

Accelerated age-related browning of human collagen in diabetes mellitus

Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine

Laminin alterations after in vitro nonenzymatic glycosylation.

Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes.

Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking.

Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats.

Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat.

Morphology and metabolism of an aortic intima-media preparation in which an intact endothelium is preserved

Glycation products and the pathogenesis of diabetic complications.

P304

1407-1411

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI116716

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

92

http://www.w3.org/2001/XMLSchema#string

P577

1993-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

8376593

http://www.w3.org/2001/XMLSchema#string

P932

288284

http://www.w3.org/2001/XMLSchema#string